BEAM240719C26000
- 0.87
- +0.42+93.33%
Beam Therapeutics Newsroom
Analysts' Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Cormedix (CRMD) and Applied Therapeutics (APLT)
Beam Therapeutics: A Hold Rating Amid Controlled R&D Spending and Upcoming Clinical Milestones
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Beam Therapeutics (BEAM) and Mirum Pharmaceuticals (MIRM)
Beam Therapeutics Analyst Ratings
Barclays Maintains Equal-Weight on Beam Therapeutics, Lowers Price Target to $33
Beam Therapeutics Analyst Ratings
Beam Therapeutics: A Buy Rating Amidst Gene Editing Industry Developments
Beam Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Beam Therapeutics (BEAM) and Glaukos (GKOS)
Beam Therapeutics: Financial and Clinical Prospects Inform Hold Rating
Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating
Beam Therapeutics Analyst Ratings
RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk
Analysts Offer Insights on Healthcare Companies: Esperion (ESPR), Beam Therapeutics (BEAM) and Opko Health (OPK)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Beam Therapeutics (BEAM), ACADIA Pharmaceuticals (ACAD) and Recursion Pharmaceuticals (RXRX)
Beam Therapeutics: Strong Buy Rating on Impressive Q4 Earnings and Promising Pipeline Developments
Barclays Reaffirms Their Hold Rating on Beam Therapeutics (BEAM)
William Blair Keeps Their Buy Rating on Beam Therapeutics (BEAM)
Wedbush Adjusts Beam Therapeutics' Price Target to $57 From $48, Keeps Outperform Rating
JP Morgan Upgrades Beam to Overweight, Cites AATD Therapy Potential